Cagrilintide: The Amylin Analog That Made the Whole Class Interesting Again

For about two decades, amylin was the metabolic hormone that everyone acknowledged and nobody could do much with. Native human amylin is notoriously badly behaved as a molecule — it aggregates into fibrils, which is exactly what you don't want in a compound you intend to study over weeks. The one amylin analog that reached the clinic, pramlintide, solved the aggregation problem but had a half-life measured in minutes. Then chemistry caught up. Cagrilintide is what happened when a medicinal-chemistry program went back and rebuilt the molecule from the sequence outward, and it has pulled the entire amylin class back into the center of metabolic research. Everything below describes published laboratory and clinical research as context only — our material is supplied for in-vitro laboratory research use, and nothing here is medical advice, a dosing suggestion, or a claim about safety or efficacy.

What the chemistry actually changed

The development paper is worth reading if you care about why this analog behaves differently from its predecessors. The design work substituted residues to stabilize the central helix, swapped in prolines to suppress the β-sheet formation that drives fibrillation, and attached a C20 fatty-acid chain to give the molecule long circulating presence via albumin binding [1]. The reported result is a compound with a half-life in the range of roughly 159–195 hours, against pramlintide's 20–45 minutes [1]. That single change — from minutes to days — is what made once-weekly research protocols possible and is the reason cagrilintide, rather than amylin itself, is the reference compound in most current work.

Which receptors it hits

Amylin receptors aren't standalone proteins. They're built from the calcitonin receptor (CTR) paired with receptor-activity-modifying proteins, giving the AMY1, AMY2 and AMY3 phenotypes. Cagrilintide is characterized as a dual amylin and calcitonin receptor agonist (DACRA) — it engages the amylin receptor complexes but also retains agonism at the bare calcitonin receptor [1]. That non-selectivity is a real feature of the pharmacology, not a footnote, and it is one reason the class is sometimes discussed separately from the newer selective amylin agonists now in development.

A 2025 mechanistic study went after the question directly using RAMP1/3 knockout mice, which lack functional AMY1 and AMY3 receptors. In wild-type animals on a high-fat diet, subchronic cagrilintide was associated with reduced food intake and body-weight loss driven by fat mass rather than lean mass; in the knockouts, that weight effect was abolished [2]. Salmon calcitonin — a comparator DACRA — behaved differently in the same model. The authors' reading is that the hindbrain AMY1/AMY3 receptors are doing the work, which is a cleaner mechanistic answer than the class had a few years ago [2].

The trial record

The dose-finding phase 2 trial published in The Lancet in 2021 is the anchor citation for cagrilintide as a standalone compound. It was a multicenter, randomized, double-blind, placebo- and active-controlled study over 26 weeks in adults with overweight or obesity, reporting dose-dependent body-weight reductions relative to placebo, with gastrointestinal events (nausea, constipation, diarrhea) as the most frequent adverse events [3]. A subsequent phase 2 trial examined cagrilintide co-administered with semaglutide in type 2 diabetes [4].

The combination — commonly written as CagriSema — is where most of the recent literature sits. The 68-week REDEFINE 1 trial randomized more than 3,000 adults with overweight or obesity across combination, semaglutide alone, cagrilintide alone, and placebo arms, and reported a substantially larger mean weight reduction in the combination arm than placebo [5]. REDEFINE 2 ran the same design in adults who also had type 2 diabetes and reported a smaller but still marked separation from placebo [6] — a pattern familiar from every incretin trial program, where diabetes cohorts consistently show less weight change than non-diabetes cohorts. For researchers, the more interesting design feature of REDEFINE 1 is the monotherapy arms: it is one of the few places you can see the amylin and GLP-1 contributions sitting side by side under the same protocol.

What the research does not establish

Several things, and they matter. The combination trials cannot cleanly separate what amylin signaling contributes versus what the GLP-1 component contributes at a mechanistic level — they establish an outcome, not an attribution. The receptor work showing hindbrain AMY1/AMY3 dependence is rodent work, and the authors present it as such [2]. Gastrointestinal tolerability was a consistent finding across studies rather than an incidental one [3]. And the long-run durability question — what happens after the trial window closes — remains open in the published record. It's also worth noting that the compounds studied in these trials were pharmaceutical-grade products administered under clinical supervision; none of that transfers to research material.

Researchers comparing mechanisms across the metabolic class often study cagrilintide alongside Tirzepatide (dual GIP/GLP-1) and Retatrutide (triple GIP/GLP-1/glucagon), since the amylin pathway is genuinely orthogonal to the incretin receptors rather than a variation on them. All are in our catalog for research use.

Research-use note: The studies above describe published laboratory and clinical research and are provided for educational reference only. K4 Elite supplies this compound strictly for in-vitro laboratory and research purposes — not for human or veterinary use, and not for diagnostic or therapeutic application. Products have not been evaluated by the FDA.